Literature DB >> 20651329

Anti-growth effect of 1,25-dihydroxyvitamin D3-3-bromoacetate alone or in combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside in pancreatic cancer cells.

Kelly S Persons1, Vikram J Eddy, Susan Chadid, Rosangela Deoliveira, Asish K Saha, Rahul Ray.   

Abstract

1,25-Dihydroxyvitamin D(3)-3-bromoacetate (1,25(OH)(2)D(3)-3-BE) is a vitamin D receptor-alkylating derivative of 1,25(OH)(2)D(3). The strong dose-dependent antiproliferative and apoptotic effects of this compound in androgen-sensitive and androgen-insensitive prostate cancer cells have been reported. In this communication, it is reported that 1,25(OH)(2)D(3)-3-BE strongly inhibits the growth of several pancreatic cancer cell lines. This effect is further accentuated by combination with 5-amino-imidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR), an activator of AMP-activated protein kinase (AMPK)/acetyl-Co-enzyme A carboxylase (ACC) phosphorylation pathways and an inhibitor of Akt phosphorylation. It was observed that the anti-growth property of 1,25(OH)(2)D(3)-3-BE, either alone or in combination with AICAR resulted in the inhibition of Akt phosphorylation in BxPC-3 cells. In conclusion, 1,25(OH)(2)D(3)-3-BE displays a strong therapeutic potential, alone and in combination with AICAR, in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20651329

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  17 in total

Review 1.  Is dietary fat, vitamin D, or folate associated with pancreatic cancer?

Authors:  G V Sanchez; S J Weinstein; R Z Stolzenberg-Solomon
Journal:  Mol Carcinog       Date:  2012-01       Impact factor: 4.784

2.  Plasma 25-hydroxyvitamin D and risk of pancreatic cancer.

Authors:  Brian M Wolpin; Kimmie Ng; Ying Bao; Peter Kraft; Meir J Stampfer; Dominique S Michaud; Jing Ma; Julie E Buring; Howard D Sesso; I-Min Lee; Nader Rifai; Barbara B Cochrane; Jean Wactawski-Wende; Rowan T Chlebowski; Walter C Willett; JoAnn E Manson; Edward L Giovannucci; Charles S Fuchs
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-11-15       Impact factor: 4.254

3.  Vitamin D-binding protein and pancreatic cancer: a nested case-control study.

Authors:  Marina R Piper; D Michal Freedman; Kim Robien; William Kopp; Helen Rager; Ronald L Horst; Rachael Z Stolzenberg-Solomon
Journal:  Am J Clin Nutr       Date:  2015-04-22       Impact factor: 7.045

4.  Prediagnostic Plasma 25-Hydroxyvitamin D and Pancreatic Cancer Survival.

Authors:  Chen Yuan; Zhi Rong Qian; Ana Babic; Vicente Morales-Oyarvide; Douglas A Rubinson; Peter Kraft; Kimmie Ng; Ying Bao; Edward L Giovannucci; Shuji Ogino; Meir J Stampfer; John Michael Gaziano; Howard D Sesso; Julie E Buring; Barbara B Cochrane; Rowan T Chlebowski; Linda G Snetselaar; JoAnn E Manson; Charles S Fuchs; Brian M Wolpin
Journal:  J Clin Oncol       Date:  2016-06-20       Impact factor: 44.544

5.  Activation of vitamin D receptor signaling downregulates the expression of nuclear FOXM1 protein and suppresses pancreatic cancer cell stemness.

Authors:  Zhiwei Li; Zhiliang Jia; Yong Gao; Dacheng Xie; Daoyan Wei; Jiujie Cui; Lopa Mishra; Suyun Huang; Yanqiao Zhang; Keping Xie
Journal:  Clin Cancer Res       Date:  2014-12-11       Impact factor: 12.531

6.  Local Sustained Delivery of 25-Hydroxyvitamin D3 for Production of Antimicrobial Peptides.

Authors:  Jiang Jiang; Guojun Chen; Franklin D Shuler; Chi-Hwa Wang; Jingwei Xie
Journal:  Pharm Res       Date:  2015-03-14       Impact factor: 4.200

7.  1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.

Authors:  Rahul Ray; James R Lambert
Journal:  Bioorg Med Chem Lett       Date:  2011-02-18       Impact factor: 2.823

Review 8.  Vitamins in pancreatic cancer: a review of underlying mechanisms and future applications.

Authors:  Ashley H Davis-Yadley; Mokenge P Malafa
Journal:  Adv Nutr       Date:  2015-11-13       Impact factor: 8.701

9.  Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy.

Authors:  Mara H Sherman; Ruth T Yu; Dannielle D Engle; Ning Ding; Annette R Atkins; Herve Tiriac; Eric A Collisson; Frances Connor; Terry Van Dyke; Serguei Kozlov; Philip Martin; Tiffany W Tseng; David W Dawson; Timothy R Donahue; Atsushi Masamune; Tooru Shimosegawa; Minoti V Apte; Jeremy S Wilson; Beverly Ng; Sue Lynn Lau; Jenny E Gunton; Geoffrey M Wahl; Tony Hunter; Jeffrey A Drebin; Peter J O'Dwyer; Christopher Liddle; David A Tuveson; Michael Downes; Ronald M Evans
Journal:  Cell       Date:  2014-09-25       Impact factor: 41.582

10.  Genetic variants in vitamin d pathway genes and risk of pancreas cancer; results from a population-based case-control study in ontario, Canada.

Authors:  Laura N Anderson; Michelle Cotterchio; Julia A Knight; Ayelet Borgida; Steven Gallinger; Sean P Cleary
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.